This research review examines how climate change and extreme weather increase morbidity across major organ systems. It highlights how rising temperatures and humidity compromise pharmaceutical stability and efficacy, particularly for vulnerable populations. The report calls for updated clinical guidelines and climate-resilient pharmaceutical regulations to safeguard public health.

This advocacy document calls for targeted investment in the One Health Joint Plan of Action. The Quadripartite collaboration proposes a Joint Offer to support at least ten countries over five years, strengthening governance, multisectoral coordination, and sustainable financing to prevent and control global health risks effectively.

This research examines the financial case for investing in One Health to mitigate global health threats. It highlights how integrated approaches reduce costs and improve efficiencies. Through various global case studies, the report demonstrates significant economic returns and provides a strategic blueprint for future sustainable investment.

This report identifies the gender health gap as a systemic market failure and significant investment opportunity. Closing this gap could boost the global economy by US$1 trillion annually by 2040. In Australia, the opportunity is valued at US$24.8 billion per year, offering a time-limited ten-year window for investors.

An interactive tracker by The Good Food Institute mapping global regulatory approvals and market pathways for cultivated meat products.

This benchmark series is an annual State of the Industry series that provides a global overview of the cultivated meat, seafood and ingredients sector. It tracks commercial developments, investment activity, scientific and technological progress, consumer insights, and government and regulatory developments, assessing the sector’s progress towards large-scale commercialisation and adoption.

This report analyses the impact of extreme temperatures on respiratory mortality across 646 Brazilian municipalities from 2010 to 2020. Findings reveal a J-shaped exposure-response curve, with heat-related deaths dominating in tropical northern regions, whilst cold-related mortality predominates in the subtropical south, underscoring the need for region-specific climate adaptation policies.

Impax Asset Management reviews sustainability-driven trends shaping healthcare, highlighting AI-enabled productivity gains, regulatory pressures, and supply chain localisation. The report examines opportunities in healthcare equipment, life sciences and managed care, alongside risks from regulation, product liability, affordability concerns and geopolitical tensions.

Institute for Health Metrics and Evaluation (IHME) is an independent global health research institute based at University of Washington. IHME produces data, metrics and analysis on disease burden, mortality, risk factors and health systems, supporting evidence-based policy, planning and health impact assessment worldwide.

This report analyses the link between ESG integration and global investor returns, drawing on cross-regional data and sector comparisons. It assesses how environmental, social, and governance factors correlate with performance, highlighting variations across markets and asset classes. The study provides evidence-based insights on ESG’s financial materiality for investors worldwide.

Water Footprint Implementation supports companies and governments with water accounting, sustainability assessment and water-footprint compensation. A spin-off of Water Footprint Network research, it delivers actionable insights for ESG reporting, water stewardship, water-footprint benchmarking and tailored reduction strategies to enhance resilience, reduce risk and foster sustainable water management.

This report examines the barriers to bringing new antibiotics to market, highlighting funding gaps, regulatory uncertainty, and weak commercial incentives. It outlines policy solutions to improve access and development, aiming to address the growing threat of antimicrobial resistance (AMR) by supporting viable pathways for pharmaceutical innovation.

Replacing Animal Research is a UK charity dedicated to ending animal testing by promoting human-relevant, non-animal research methods. Through funding scientific projects, publishing the peer-reviewed journal ATLA, and engaging in education and policy advocacy, it aims to create a world where no animal suffers for science.

This report examines how environmental, social, and governance (ESG) factors are being adopted in venture capital. It outlines current practices, challenges, and industry-specific considerations, and highlights the need for tailored guidance, collaboration, and early-stage engagement to advance responsible investment across the venture capital ecosystem.

The report outlines how strategic investment can reduce animal testing in the health sector. It provides investors with guidance on promoting transparency, encouraging non-animal methods, and influencing regulation, while highlighting the risks of limited disclosure and misalignment with consumer concerns.

This study examines the visibility of climate-related disclosures in reports from 28 large Australian ASX50 firms during 2022. It finds that disclosures on physical climate risks are generally limited and superficial, whereas opportunities from the transition to a low-carbon economy are more prominently highlighted, indicating selective disclosure practices across sectors.